Business ❯ Pharmaceutical Industry

Acquisitions

Biotechnology Foreign Investment Sanofi Research and Development Financial Outlook Drug Development J.P. Morgan Healthcare Conference Bristol Myers Squibb Drug Pricing Johnson & Johnson Intra-Cellular Therapies

Novartis Strikes $2 Billion Deal for Mutant-Selective PI3Kα Cancer Drug SNV4818

The Phase 1/2 asset targets PIK3CA‑mutant tumors to improve tolerability in HR+/HER2‑ breast cancer with closing expected in the first half of 2026.

Takeda’s AI-Assisted Psoriasis Pill Succeeds in Phase 3, Outperforms Otezla

Ianalumab Plus Eltrombopag Extends Disease Control in Phase 3 ITP Study Published in NEJM

FDA Approves J&J’s Caplyta for Major Depressive Disorder

Sanofi’s Efdoralprin Alfa Shows Superior Biomarker Response to Plasma Therapy in Phase 2 AATD Trial